DeepCure

DeepCure is an AI-driven drug discovery company developing novel small molecule therapeutics for immune and inflammatory diseases.

Health Tech & Life Sciences
Active
Series A Boston, United States Founded 2018
Last updated 2026-07-26
Total raised
$46.0M
Last: Undisclosed Round 2021-11
Stage
Series A
Founded
2018
Headcount
49
HQ
Boston, United States
Sector
Health Tech & Life Sciences

About

DeepCure is a biotech company that discovers transformative small molecule therapies for immune and inflammatory diseases. The company utilizes a chemistry platform that integrates AI, physics-based tools, and automated chemical synthesis to identify novel molecules. DeepCure's platform leverages deep learning algorithms, cloud computing, and a proprietary chemistry database to accelerate the creation of novel small molecule therapies.

Funding history · 2 rounds · $46.0M total

2021-10
A Round $40.0M
★ Morningside Venture InvestmentsTLV PartnersSapir Venture Partners
2019-07
Seed $6.0M
★ TLV Partners★ Sapir Venture Partners

Headcount over time

From 2 (2019-04) to 31 (2025-12) · +29 (+1450%) · 48 points · source: Finder history + radar grounding
520 2019-04 2025-12

Q&A

What is DeepCure's primary focus?
DeepCure is an AI-driven drug discovery company that develops novel small molecule therapeutics for immune and inflammatory diseases.
What is DeepCure's total funding to date?
DeepCure has raised a total of $71.4 million USD.
When did DeepCure close its most recent funding round and who led it?
In April 2024, DeepCure closed an A Round of $24.6 million USD, led by IAG Capital Partners.
Who are the co-founders of DeepCure?
The co-founders of DeepCure are Kfir Schreiber (CEO), Joseph Jacobson, and Thrasyvoulos Karydis (CTO).
What is the core technology behind DeepCure's drug discovery platform?
DeepCure utilizes a chemistry platform that integrates AI, physics-based tools, and automated chemical synthesis to identify novel molecules, leveraging deep learning algorithms, cloud computing, and a proprietary chemistry database.
What was a significant collaboration announced by DeepCure in January 2023?
In January 2023, DeepCure collaborated with Biosero to establish a fully automated, AI-powered chemistry synthesis platform.

Team · 3

Kfir Schreiber
Founder · CEO & Co-Founder
Joseph Jacobson
Founder · Co-Founder
Thrasyvoulos Karydis
Founder · CTO & Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Artificial IntelligenceDeep Learning
Target customers
Healthcare & Life SciencesLife SciencesBiotechnologyPharmaceuticals
Business model
B2B

Tags

drug-developmentdrug-discoverybiotechnologypharmaceuticalsartificial-intelligencedeep-learning
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websitedeepcure.com
LinkedInlinkedin.com/company/18557550

Identifiers & details

Founded2018
Employees (exact)49
OfficesBoston

Radar intelligence

Patents

EPO25

Web history (Wayback)

Domaindeepcure.com

Certificate / subdomain footprint

Subdomains7

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516567518
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2022-02-22
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events0
Registered addressליפסקי לואי 9 תל אביב - יפו